SUMMARY
Patients with myasthenia gravis demonstrate resistance to suxamethonium and have an increased sensitivity to non-depolarizing muscle relaxants which is often variable and unpredictable 1, 2 . Avoidance of muscle paralysis facilitates perioperative management, allowing early recovery of muscle function. Laryngeal mask airways are less invasive than endotracheal tubes and allow the avoidance of paralysis, but may not be suitable for positive pressure ventilation. The ProSeal laryngeal mask airway (PLMA) is a new laryngeal mask with a modified cuff and a drainage tube. The PLMA has been shown to give an effective glottic seal in patients undergoing positive pressure ventilation [3] [4] [5] 5, 6 and to be an effective ventilatory device in healthy female patients 6 . We describe the successful use of the PLMA in the perioperative management of a patient with myasthenia gravis undergoing a mastectomy with axillary clearance by allowing positive pressure ventilation without the use of muscle relaxants.
CASE REPORT
A 70-year-old, 68 kg, 158 cm female patient, was admitted for a mastectomy and axillary lymph node clearance for a T1 N1 M0 carcinoma of the breast. She had presented six years previously with a history of progressive weakness which was diagnosed as generalized myasthenia gravis on the basis of a positive edrophonium test. She did not undergo a thymectomy and was treated with medical therapy. For two years prior to surgery she had been on pyridostigmine 180 mg daily, azathioprine 150 mg daily and prednisone 10 mg on alternate days.
Preoperatively she was classified as Grade 2A myasthenia on the basis of mild weakness with fatiguability on effort and no bulbar dysfunction. She was a smoker of 2 to 5 cigarettes per day for many years and had no other evidence of respiratory disease. On examination power was moderately diminished globally with demonstrable fatigue.
Pulmonary function testing showed a forced expiratory volume in 1 second (FEV 1 ) of 1990 ml and a forced vital capacity (FVC) of 2670 ml with a FEV 1 /FVC ratio of 75%. Maximum inspiratory pressure (MIP) was -35 cmH 2 O and her maximum expiratory pressure (MEP) was +45 cmH 2 O.
Preoperatively she was not premedicated and all medication was omitted. In theatre intravenous access was established and glycopyrrolate 0.8 mg as well as hydrocortisone 100 mg were given intravenously. Anaesthesia was induced with fentanyl 75 µg followed three minutes later by propofol 130 mg and maintained with halothane 0.5 to 2% in nitrous oxide and 30% oxygen at a fresh gas flow of 3 l/min in a circle system. A size 4 PLMA was inserted at the first attempt using the introducer tool with the recommended technique of Fastrach™ (Intavent, Orthofix, Maidenhead, United Kingdom) insertion as described by the manufacturer 7 . The cuff of the mask was inflated with air 30 ml to obtain an intracuff pressure of 60 cmH 2 O. The lungs were easily ventilated obtaining exhaled tidal volumes of >8 ml/kg -1 with a peak inspiratory pressure of 12 cmH 2 O. Adequate position of the mask was determined as recommended by Brain 3 by sealing the proximal end of the drainage tube with lubricating jelly, pressurizing the breathing system, and noting the pressure at which gas leakage occurred. Leakage occurred from the mouth at 30 cmH 2 O. Gastric tube placement through the drainage tube of the PLMA was easily achieved with no gastric contents aspirated initially and 10 ml aspirated at the end of the procedure. The patient was mechanically ventilated throughout the procedure. She did not receive or require any neuromuscular blocking drugs. Analgesia was administered with a remifentanil infusion at a rate of 0.25 µg/ kg/min; a total dose of 1 mg was given during the two hour procedure. Morphine 2 mg was given intravenously ten minutes before closure.
The rate of mechanical ventilation was decreased at this time and the patient resumed spontaneous ventilation. On awakening, when the patient could open her mouth to command, the PLMA was deflated and removed. She was transferred to a high care unit where her vital capacity was measured at 2.4 litres. She received pyridostigmine 60 mg orally three hours later. She required only paracetamol and nonsteroidal anti-inflammatory drugs for postoperative pain control. The following day her usual medical therapy was recommenced and she was discharged from hospital. Her vital capacity measured prior to discharge had recovered to the preoperative value of 2.6 litres.
DISCUSSION
Patients who have myasthenia gravis most commonly undergo surgery for thymectomy as part of the management of their disease. Routine airway management in these cases involves intubation and ventilation. Approximately 50% of patients with myasthenia gravis undergoing thymectomy require elective postoperative ventilation 8 , while all patients require postoperative monitoring of respiratory function even if only small doses of muscle relaxants are used as they are at a higher risk of postoperative respiratory failure 9 . According to Leventhal 10 , predictors of the need to ventilate the patient electively postoperatively include a long-standing history of the disease (>6 years), a vital capacity of <40 ml/kg, pyridostigmine dosage of >750 mg/day and the presence of concomitant lung disease. These predictors have been found to be unreliable in patients with myasthenia gravis undergoing surgery other than thymectomy 11 , and their reliability even in patients undergoing thymectomy has recently been questioned 12 . This report suggested that anaesthetic technique, particularly the use of neuromuscular blocking drugs, is a more important predictor of the need for postoperative ventilation. Other factors such as duration and extent of surgery are also important in determining the need for postoperative ventilation in myasthenic patients.
The perioperative administration of pyridostigmine in myasthenic patients is controversial. Withholding the morning dose of pyridostigmine is beneficial in utilizing the patient's natural weakness to facilitate intubation, ventilation and surgery, as well as in decreasing bronchial secretions 13 . Alternatively, continuing with preoperative pyridostigmine may allow for planned extubation in those patients with an adequate preoperative vital capacity 14 . In our case, the omission of the morning dose of pyridostigmine may have contributed to the ease of positive pressure ventilation, while the avoidance of any neuromuscular blockers intraoperatively and the early commencement of postoperative pyridostigmine may have contributed to the prompt recovery of the patient to her preoperative state.
Patients with myasthenia gravis have an unpredictable and variable clinical response to neuromuscular blocking agents and differing techniques are described to avoid their use. Ruiz-Neto 15 describes an inhalation induction technique utilizing the muscle relaxant properties of an inhalational agent to intubate the trachea. An alternative technique is to use small doses of shorter acting agents such as vecuronium and mivacurium to avoid the cardiorespiratory side-effects of deep inhalational anaesthesia and carefully monitor for return of muscle power. Peripheral nerve testing may be misleading in that it may recover while the pharyngeal muscles and those required to protect the airway are still partially paralysed. This differential response may be more evident in patients with myasthenia gravis 14 . We used halothane as the inhalational agent in this patient. Isoflurane produces twice as much twitch height depression as equipotent concentrations of halothane in myasthenic patients 16 . Enflurane decreases twitch height to a variable degree 17 , while sevoflurane appears to depress neuromuscular transmission to the same degree as isoflurane in myasthenia 18 . No data is available for desflurane in myasthenic patients 13 . Isoflurane or sevoflurane may therefore have been preferable in our patient in order to achieve optimum conditions for positive pressure ventilation. However, using halothane and a remifentanil infusion together with the PLMA achieved ventilation at a low peak inspiratory pressure, and may have resulted in less postoperative residual muscle weakness.
There is only one published case report describing the intraoperative airway management of myasthenic patients undergoing surgery other than thymectomy 19 . This describes the successful use of a classic laryngeal mask airway (LMA) in a patient with myasthenia gravis undergoing laparoscopic cholecystectomy. Combined thoracic epidural and general anaesthesia using a classic laryngeal mask with spontaneous ventilation was chosen. The stomach was emptied with a gastric tube.
The LMA is advantageous in patients with myasthenia gravis as its use is associated with a lower airway resistance, decreased work of breathing and less triggering of bronchospasm compared with an endotracheal tube 20, 21 . Importantly, laryngeal mask placement does not require muscle relaxation. However, the use of the classic LMA for positive pressure ventilation has recently been questioned 22 due to the risk of regurgitation and aspiration.
The ProSeal laryngeal mask (PLMA) is a new laryngeal mask device with a modified cuff to improve the seal around the glottis and a drainage tube to provide a bypass channel for regurgitated gastric contents, prevent gastric insufflation and allow the passage of a gastric tube. These features are designed to improve the safety of the mask and broaden its scope, especially when used with positive pressure ventilation 3 . Initial trials in small numbers of patients 3, 4 showed the PLMA capable of allowing positive pressure ventilation without gastric insufflation, obtaining a glottic seal 10 to 12 cmH 2 O higher than the classic LMA and allowing the easy passage of a gastric tube. A recently published trial confirmed these findings in 117 patients ventilated with the PLMA 5 . All patients were ventilated adequately with no episodes of gastric insufflation, although gastric insufflation can occur if the tip of the mask folds over during insertion 23, 24 . Brimacombe showed recently that the PLMA was an effective ventilatory device in healthy females, with less leakage of air from the mouth occurring than with the classic LMA 6 . With the reported incidence of aspiration with the use of the classic LMA being 1 in 11,000 25 , a randomized, controlled trial with sufficient power to show a 50% reduction in aspiration with the use of the PLMA would require 1.5 million patients in each group 25 and therefore is unlikely to ever be performed. A cadaver trial has shown the PLMA capable of isolating the glottis from fluid pumped up the oesophagus 26 , and a recent clinical trial has shown the PLMA able to isolate the glottis from fluid present in the pharynx 27 . Recent case reports describe the PLMA protecting against fluid aspiration intraoperatively 29, 30 and during airway management in the ICU 30 . In our case the airway was established with the PLMA without the use of neuromuscular blocking agents or deep inhalational anaesthesia. Mechanical ventilation was used intraoperatively, preventing hypoventilation and minimizing respiratory muscle fatigue, allowing early return of preoperative muscle function and an early discharge.
The PLMA may facilitate IPPV without muscle relaxants in patients with myasthenia gravis undergoing surgery where an endotracheal tube is not indicated.
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